Volume 23, Number 6—June 2017
Penicillin Resistance of Nonvaccine Type Pneumococcus before and after PCV13 Introduction, United States
Views: Views equals page views plus PDF downloadsMetric Details
Highlight and copy the desired format.
|EID||Andam CP, Worby CJ, Gierke R, McGee L, Pilishvili T, Hanage WP, et al. Penicillin Resistance of Nonvaccine Type Pneumococcus before and after PCV13 Introduction, United States. Emerg Infect Dis. 2017;23(6):1012-1015. https://dx.doi.org/10.3201/eid2306.161331|
|AMA||Andam CP, Worby CJ, Gierke R, et al. Penicillin Resistance of Nonvaccine Type Pneumococcus before and after PCV13 Introduction, United States. Emerging Infectious Diseases. 2017;23(6):1012-1015. doi:10.3201/eid2306.161331.|
|APA||Andam, C. P., Worby, C. J., Gierke, R., McGee, L., Pilishvili, T., & Hanage, W. P. (2017). Penicillin Resistance of Nonvaccine Type Pneumococcus before and after PCV13 Introduction, United States. Emerging Infectious Diseases, 23(6), 1012-1015. https://dx.doi.org/10.3201/eid2306.161331.|
Introduction of 13-valent pneumococcal conjugate vaccine in the United States was not associated with a significant change in prevalence of penicillin resistance in nonvaccine type serotypes because of the variable success of highly resistant serotypes. Differences in regional serotype distribution and serotype-specific resistance contributed to geographic heterogeneity of penicillin resistance.
Streptococcus pneumoniae (pneumococcus) causes a range of debilitating and potentially life-threatening infections, such as pneumonia, meningitis, and septicemia. To reduce illness and death caused by pneumococcal diseases, a 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in 2000 and targeted serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. However, although vaccine type serotypes declined in frequency after PCV7 introduction (1,2), an increasing frequency of nonvaccine type (NVT) serotypes in samples from carriage and invasive disease was observed in subsequent years (2,3). Known as serotype replacement, this population-level change in serotype distribution, which most often involves preexisting clones and serotypes that were already in circulation before vaccine implementation (4), can reduce the benefits of vaccination (5). To address the rise in invasive pneumococcal disease associated with NVT serotypes, a second-generation conjugate vaccine was implemented in 2010 (PCV13), targeting the 7 serotypes targeted by PCV7 plus 6 additional serotypes: 1, 3, 5, 6A, 7F, and 19A (6).
The prevalence of penicillin-resistant pneumococcus strains varies considerably between states (7,8). Such variation might be caused by differences in serotype distribution (such that some locations have a higher prevalence of strains that are generally more resistant) or higher-than-average levels of resistance within serotypes. Before the introduction of PCV7, regional variations in the prevalence of antibiotic resistance were considered to be caused by regional differences in antibiotic use, leading to differences in the intensity of selective pressure acting on the bacterial population (9). The variation in the proportion of resistant isolates within individual serotypes in the United States was thought to be a reflection of this regional difference in antibiotic use and was identified as the major factor in driving geographic variation of penicillin resistance (7). However, post-PCV7, this factor played a diminishing role in explaining geographic heterogeneity in penicillin resistance, with variation in serotype distribution between sites being of increasing importance (8). Understanding the underlying causes of the geographic heterogeneity of penicillin resistance and the role of selective pressure provides important insights on the long-term dynamics of penicillin resistance in the United States.
To analyze NVT penicillin-nonsusceptible pneumococcus (PNSP) detected in patients with invasive pneumococcal disease, we used data from the Active Bacterial Core surveillance (ABCs) system, a population- and laboratory-based collaborative system between the Centers for Disease Control and Prevention and state health departments and academic institutions in 10 states (California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, and Tennessee). We considered PNSP non-PCV13 serotypes detected in patients in all age groups from 2009 (pre-PCV13, n = 285 patients) through 2012 (post-PCV13, 339 patients). Nonsusceptibility was based on the meningitis breakpoint (MIC >0.12 μg/mL), as recommended by the Clinical and Laboratory Standards Institute (10). Serotypes 15B, 15C, and 15B/C were grouped together as 15BC because of the reported reversible switching between the 2 serotypes, which makes the precise differentiation of these serotypes difficult (11).
To determine whether geographic differences in the proportions of PNSP were consistent across serotypes, we calculated the proportions of PNSP for each of the 7 most common NVT serotypes (15A, 15BC, 16F, 23A, 23B, 33F, and 35B) across the 10 sites for 2009 and 2012. We found that serotypes with the highest proportions of PNSP in 2012 already had high resistance in 2009 (Figure 1). We calculated the Spearman correlation coefficient between the proportion of PNSP for each pair of serotypes across states in 2009 (range –0.09 to 0.66) and 2012 (range 0.30–0.79) (Technical Appendix [PDF - 324 KB - 11 pages]). We found significant overall correlation in 2009 and 2012 (p<0.001 for both years), indicating that sites with high proportions of PNSP in 1 serotype typically will also have high proportions of PNSP in other serotypes. This finding suggests that differences in selection pressure account for the geographic variation in the proportions of PNSP.
We next implemented a standardized regression approach, used previously to analyze the pneumococcal-resistance patterns pre-PCV7 (7) and post-PCV7 (8) (Technical Appendix [PDF - 324 KB - 11 pages]). To investigate the source of geographic variation in the proportion of PNSP, we tested the hypotheses that either geographic heterogeneity in serotype distribution (Std1), or serotype-specific differences in penicillin resistance (Std2) were responsible for the observed variation. These effects were quantified by regressing crude versus standardized prevalence of penicillin resistance (Figure 2; Technical Appendix [PDF - 324 KB - 11 pages]), by which a regression slope of 1 would indicate that the factor considered had zero effect. By using 2009 data, we found that regression slopes for Std1 (0.445, 95% CI –0.083 to 0.972) and Std2 (0.463, 95% CI –0.013 to 0.939) indicate that both factors played a similar intermediate role in generating this geographic variation in penicillin resistance, with neither 95% CI containing 1. In 2012, the regression coefficient for Std2 was higher (0.634, 95% CI 0.14–1.128), whereas the coefficient for Std1 decreased (0.367, 95% CI –0.025 to 0.758). Although these changes are not statistically significant relative to 2009, they might suggest shifting contributions to the observed variation in proportions of PNSP after the introduction of the PCV13 vaccine in 2010, with geographic differences in serotype distribution having an increased role and differences in serotype-specific PNSP becoming less important.
Finally, we sought to quantify the rate of change in penicillin resistance during 2009–2012 in each state. We documented the proportion of PNSP by state for the pre- and post-PCV13 periods (Technical Appendix [PDF - 324 KB - 11 pages] Table 4). No significant change in state-level resistance was observed. New Mexico, Maryland, and Georgia saw the highest increases in the proportion of PNSP during 2009–2012, whereas a slight decline was observed for Colorado, New York, and Connecticut. Although the distribution of serotypes might greatly fluctuate among geographic regions immediately after vaccine introduction, the overall proportions of NVT serotypes with penicillin resistance across the country might not vary significantly between the pre- and post-vaccine periods. Of potential importance are the small increases in the proportions of PNSP serotypes not included in either vaccine that were observed between the implementation of PCV7 and PCV13 (12), which might lay the foundation for changes post-PCV13.
The marked variation in the proportion of penicillin resistance among states highlights the potential of local selective pressures to favor certain serotypes and resistant strains within each serotype to increase in frequency as the population returns to equilibrium (13). Previous studies have already shown significant regional differences in antibiotic use and vaccination coverage across the United States (14,15). Regional rates of patient adherence to treatment regimens will also influence variations in resistance. A combination of these factors, which will likely vary between and within regions, would greatly affect proportions of resistance across the country.
In our study, we observed that the dynamics of penicillin resistance continue to shift in the wake of vaccine introduction. Our postvaccine observations were recorded shortly after the introduction of the vaccine; additional observations would be valuable to determine the stability of the postvaccine dynamics and any potential importance of the temporal changes we observed to factors contributing to variation in resistance levels. Further long-term nationwide surveillance of serotype dynamics is required to assess the multiple ecologic factors that influence antibiotic resistance in the pneumococcus in the conjugate vaccine era.
Dr. Andam is a postdoctoral fellow at the Department of Epidemiology at the Harvard T.H. Chan School of Public Health. Her research focuses on using genomic data to understand the population structure and evolution of pneumococcus.
We thank the principal investigators and surveillance officers at the 10 participating ABCs sites and the ABCs Epidemiology and Streptococcal Laboratory teams at the Centers for Disease Control and Prevention.
W.P.H. was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (award no. R01 AI106786-01). C.J.W. was supported by the National Institute of General Medical Sciences of the National Institutes of Health (award no. U54GM088558).
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the institutions with which the authors are affiliated. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
- Hsu KK, Shea KM, Stevenson AE, Pelton SI; Massachusetts Department of Public Health. Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007. Pediatr Infect Dis J. 2010;29:289–93.
- Scott JR, Millar EV, Lipsitch M, Moulton LH, Weatherholtz R, Perilla MJ, et al. Impact of more than a decade of pneumococcal conjugate vaccine use on carriage and invasive potential in Native American communities. J Infect Dis. 2012;205:280–8.
- Huang SS, Platt R, Rifas-Shiman SL, Pelton SI, Goldmann D, Finkelstein JA. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics. 2005;116:e408–13.
- Croucher NJ, Finkelstein JA, Pelton SI, Mitchell PK, Lee GM, Parkhill J, et al. Population genomics of post-vaccine changes in pneumococcal epidemiology. Nat Genet. 2013;45:656–63.
- Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011;378:1962–73.
- Jefferies JMC, Macdonald E, Faust SN, Clarke SC. 13-valent pneumococcal conjugate vaccine (PCV13). Hum Vaccin. 2011;7:1012–8.
- McCormick AW, Whitney CG, Farley MM, Lynfield R, Harrison LH, Bennett NM, et al. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med. 2003;9:424–30.
- Link-Gelles R, Thomas A, Lynfield R, Petit S, Schaffner W, Harrison L, et al. Geographic and temporal trends in antimicrobial nonsusceptibility in Streptococcus pneumoniae in the post-vaccine era in the United States. J Infect Dis. 2013;208:1266–73.
- Hicks LA, Chien Y-W, Taylor TH Jr, Haber M, Klugman KP; Active Bacterial Core Surveillance (ABCs) Team. Outpatient antibiotic prescribing and nonsusceptible Streptococcus pneumoniae in the United States, 1996-2003. Clin Infect Dis. 2011;53:631–9.
- Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 16th informational supplement (M100–S16). Wayne (PA): The Institute; 2008.
- Venkateswaran PS, Stanton N, Austrian R. Type variation of strains of Streptococcus pneumoniae in capsular serogroup 15. J Infect Dis. 1983;147:1041–54.
- Gertz RE Jr, Li Z, Pimenta FC, Jackson D, Juni BA, Lynfield R, et al.; Active Bacterial Core Surveillance Team. Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. J Infect Dis. 2010;201:770–5.
- Hanage WP, Bishop CJ, Lee GM, Lipsitch M, Stevenson A, Rifas-Shiman SL, et al. Clonal replacement among 19A Streptococcus pneumoniae in Massachusetts, prior to 13 valent conjugate vaccination. Vaccine. 2011;29:8877–81.
- Suda KJ, Hicks LA, Roberts RM, Hunkler RJ, Taylor TH. Trends and seasonal variation in outpatient antibiotic prescription rates in the United States, 2006 to 2010. Antimicrob Agents Chemother. 2014;58:2763–6.
- Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease and 13-valent pneumococcal conjugate vaccine (PCV13) coverage among children aged ≤59 months---selected U.S. regions, 2010--2011. MMWR Morb Mortal Wkly Rep. 2011;60:1477–81.
Technical AppendixCite This Article
1These first authors contributed equally to this article.
- Page created: May 16, 2017
- Page last updated: May 16, 2017
- Page last reviewed: May 16, 2017
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)